{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:24:26Z","timestamp":1786962266980,"version":"build-2736575974"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"20","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["RO1CA236389"],"award-info":[{"award-number":["RO1CA236389"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Carol M. Baldwin Breast Cancer Research Award"},{"name":"Stony Brook Center for Healthy Aging Award"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Rep"],"published-print":{"date-parts":[[2025,10,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Oncogenic KRAS mutations underlie some of the deadliest human cancers. Genetic or pharmacological KRAS inactivation produces mixed outcomes and frequent relapse. Mechanisms of tumor resistance to KRAS inhibition remain poorly understood. We present evidence that STAT3 supports tumor growth following KRAS depletion. Using a conceptual framework of pancreatic ductal adenocarcinoma, we show that cancer cells that survive CRISPR-mediated ablation of mutant KRAS are dependent on STAT3 function to maintain tumorigenicity. Mechanistically, the combined loss of mutant KRAS and STAT3 disrupts a core transcriptional program of cancer cells critical to oncogenic competence. This in turn impairs tumor growth in mice and enhances immune rejection, leading to tumor clearance. We propose that the STAT3 transcriptional program operating in cancer cells enforces their malignant identity, rather than providing classical features of transformation, and shapes cancer persistence following KRAS inactivation. Our findings establish STAT3 as a critical enforcer of oncogenic identity in KRAS-ablated tumors, revealing a key vulnerability.<\/jats:p>","DOI":"10.1038\/s44319-025-00563-w","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T14:20:32Z","timestamp":1756218032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["STAT3 sustains tumorigenicity following mutant KRAS ablation"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6425-7822","authenticated-orcid":false,"given":"Stephen","family":"D\u2019Amico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varvara","family":"Kirillov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijuan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5049-6188","authenticated-orcid":false,"given":"Xinyuan","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S","family":"Sheridan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4367-6097","authenticated-orcid":false,"given":"Nancy C","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"563_CR1","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23324-4","volume":"12","author":"M Andreatta","year":"2021","unstructured":"Andreatta M, Corria-Osorio J, Muller S, Cubas R, Coukos G, Carmona SJ (2021) Interpretation of T cell states from single-cell transcriptomics data using reference atlases. Nat Commun 12:2965","journal-title":"Nat Commun"},{"key":"563_CR2","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc1048","volume":"373","author":"A Baggiolini","year":"2021","unstructured":"Baggiolini A, Callahan SJ, Montal E, Weiss JM, Trieu T, Tagore MM, Tischfield SE, Walsh RM, Suresh S, Fan Y et al (2021) Developmental chromatin programs determine oncogenic competence in melanoma. Science 373:eabc1048","journal-title":"Science"},{"key":"563_CR3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC et al (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531:47\u201352","journal-title":"Nature"},{"key":"563_CR4","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.3390\/ijms22136995","volume":"22","author":"AJ Boutilier","year":"2021","unstructured":"Boutilier AJ, Elsawa SF (2021) Macrophage polarization states in the tumor microenvironment. Int J Mol Sci 22:6995","journal-title":"Int J Mol Sci"},{"key":"563_CR5","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1158\/1535-7163.MCT-20-0462","volume":"20","author":"DM Briere","year":"2021","unstructured":"Briere DM, Li S, Calinisan A, Sudhakar N, Aranda R, Hargis L, Peng DH, Deng J, Engstrom LD, Hallin J et al (2021) The KRAS(G12C) inhibitor MRTX849 reconditions the tumor immune microenvironment and sensitizes tumors to checkpoint inhibitor therapy. Mol Cancer Ther 20:975\u2013985","journal-title":"Mol Cancer Ther"},{"key":"563_CR6","doi-asserted-by":"crossref","first-page":"e49707","DOI":"10.1371\/journal.pone.0049707","volume":"7","author":"MA Collins","year":"2012","unstructured":"Collins MA, Brisset JC, Zhang Y, Bednar F, Pierre J, Heist KA, Galban CJ, Galban S, di Magliano MP (2012) Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PLoS ONE 7:e49707","journal-title":"PLoS ONE"},{"key":"563_CR7","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm.2344","volume":"17","author":"EA Collisson","year":"2011","unstructured":"Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L et al (2011) Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 17:500\u2013503","journal-title":"Nat Med"},{"key":"563_CR8","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1158\/0008-5472.CAN-11-0908","volume":"71","author":"RB Corcoran","year":"2011","unstructured":"Corcoran RB, Contino G, Deshpande V, Tzatsos A, Conrad C, Benes CH, Levy DE, Settleman J, Engelman JA, Bardeesy N (2011) STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res 71:5020\u20135029","journal-title":"Cancer Res"},{"key":"563_CR9","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41588-022-01157-1","volume":"54","author":"D Cui Zhou","year":"2022","unstructured":"Cui Zhou D, Jayasinghe RG, Chen S, Herndon JM, Iglesia MD, Navale P, Wendl MC, Caravan W, Sato K, Storrs E et al (2022) Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer. Nat Genet 54:1390\u20131405","journal-title":"Nat Genet"},{"key":"563_CR11","doi-asserted-by":"crossref","first-page":"RP92559","DOI":"10.7554\/eLife.92559.2","volume":"13","author":"S D\u2019Amico","year":"2024","unstructured":"D\u2019Amico S, Kirillov V, Petrenko O, Reich NC (2024) STAT3 is a genetic modifier of TGF-beta induced EMT in KRAS mutant pancreatic cancer. eLife 13:RP92559","journal-title":"eLife"},{"key":"563_CR12","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1101\/gad.311852.118","volume":"32","author":"S D\u2019Amico","year":"2018","unstructured":"D\u2019Amico S, Shi J, Martin BL, Crawford HC, Petrenko O, Reich NC (2018) STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis. Genes Dev 32:1175\u20131187","journal-title":"Genes Dev"},{"key":"563_CR13","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1038\/sj.onc.1208469","volume":"24","author":"DJ Dauer","year":"2005","unstructured":"Dauer DJ, Ferraro B, Song L, Yu B, Mora L, Buettner R, Enkemann S, Jove R, Haura EB (2005) Stat3 regulates genes common to both wound healing and cancer. Oncogene 24:3397\u20133408","journal-title":"Oncogene"},{"key":"563_CR14","doi-asserted-by":"crossref","first-page":"D1016","DOI":"10.1093\/nar\/gkae1080","volume":"53","author":"I Diamant","year":"2025","unstructured":"Diamant I, Clarke DJB, Evangelista JE, Lingam N, Ma\u2019ayan A (2025) Harmonizome 3.0: integrated knowledge about genes and proteins from diverse multi-omics resources. Nucleic Acids Res 53:D1016\u2013D1028","journal-title":"Nucleic Acids Res"},{"key":"563_CR15","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ccr.2011.03.002","volume":"19","author":"Fukuda","year":"2011","unstructured":"Fukuda, Wang A, Morris SC, JPt, Folias AE, Liou A, Kim GE, Akira S, Boucher KM, Firpo MA, Mulvihill SJ et al (2011) Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 19:441\u2013455","journal-title":"Cancer Cell"},{"key":"563_CR16","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1101\/gad.1752608","volume":"22","author":"N Gao","year":"2008","unstructured":"Gao N, LeLay J, Vatamaniuk MZ, Rieck S, Friedman JR, Kaestner KH (2008) Dynamic regulation of Pdx1 enhancers by Foxa1 and Foxa2 is essential for pancreas development. Genes Dev 22:3435\u20133448","journal-title":"Genes Dev"},{"key":"563_CR17","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26950-0","volume":"12","author":"RJ Geusz","year":"2021","unstructured":"Geusz RJ, Wang A, Lam DK, Vinckier NK, Alysandratos KD, Roberts DA, Wang J, Kefalopoulou S, Ramirez A, Qiu Y et al (2021) Sequence logic at enhancers governs a dual mechanism of endodermal organ fate induction by FOXA pioneer factors. Nat Commun 12:6636","journal-title":"Nat Commun"},{"key":"563_CR18","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A (2023) Pancreatic cancer: advances and challenges. Cell 186:1729\u20131754","journal-title":"Cell"},{"key":"563_CR19","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41575-021-00463-z","volume":"18","author":"A Hayashi","year":"2021","unstructured":"Hayashi A, Hong J, Iacobuzio-Donahue CA (2021) The pancreatic cancer genome revisited. Nat Rev Gastroenterol Hepatol 18:469\u2013481","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"563_CR20","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1053\/j.gastro.2017.12.005","volume":"154","author":"P He","year":"2018","unstructured":"He P, Yang JW, Yang VW, Bialkowska AB (2018) Kruppel-like factor 5, increased in pancreatic ductal adenocarcinoma, promotes proliferation, acinar-to-ductal metaplasia, pancreatic intraepithelial neoplasia, and tumor growth in mice. Gastroenterology 154:1494\u20131508.e1413","journal-title":"Gastroenterology"},{"key":"563_CR21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","volume":"7","author":"SR Hingorani","year":"2005","unstructured":"Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7:469\u2013483","journal-title":"Cancer Cell"},{"key":"563_CR22","doi-asserted-by":"crossref","first-page":"e165734","DOI":"10.1172\/JCI165734","volume":"134","author":"MH Hsieh","year":"2024","unstructured":"Hsieh MH, Wei Y, Li L, Nguyen LH, Lin YH, Yong JM, Sun X, Wang X, Luo X, Knutson SK et al (2024) Liver cancer initiation requires translational activation by an oncofetal regulon involving LIN28 proteins. J Clin Invest 134:e165734","journal-title":"J Clin Invest"},{"key":"563_CR23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jim.2009.06.008","volume":"347","author":"Y Hu","year":"2009","unstructured":"Hu Y, Smyth GK (2009) ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 347:70\u201378","journal-title":"J Immunol Methods"},{"key":"563_CR24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41568-018-0090-8","volume":"19","author":"J Huynh","year":"2019","unstructured":"Huynh J, Chand A, Gough D, Ernst M (2019) Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map. Nat Rev Cancer 19:82\u201396","journal-title":"Nat Rev Cancer"},{"key":"563_CR25","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-21736-w","volume":"12","author":"I Ischenko","year":"2021","unstructured":"Ischenko I, D\u2019Amico S, Rao M, Li J, Hayman MJ, Powers S, Petrenko O, Reich NC (2021) KRAS drives immune evasion in a genetic model of pancreatic cancer. Nat Commun 12:1482","journal-title":"Nat Commun"},{"key":"563_CR26","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.it.2023.09.002","volume":"44","author":"KH Johansen","year":"2023","unstructured":"Johansen KH, Golec DP, Okkenhaug K, Schwartzberg PL (2023) Mind the GAP: RASA2 and RASA3 GTPase-activating proteins as gatekeepers of T cell activation and adhesion. Trends Immunol 44:917\u2013931","journal-title":"Trends Immunol"},{"key":"563_CR27","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.gde.2010.06.005","volume":"20","author":"KH Kaestner","year":"2010","unstructured":"Kaestner KH (2010) The FoxA factors in organogenesis and differentiation. Curr Opin Genet Dev 20:527\u2013532","journal-title":"Curr Opin Genet Dev"},{"key":"563_CR28","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41577-019-0223-7","volume":"20","author":"A Kallies","year":"2020","unstructured":"Kallies A, Zehn D, Utzschneider DT (2020) Precursor exhausted T cells: key to successful immunotherapy?. Nat Rev Immunol 20:128\u2013136","journal-title":"Nat Rev Immunol"},{"key":"563_CR29","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/nprot.2009.171","volume":"4","author":"MP Kim","year":"2009","unstructured":"Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE (2009) Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc 4:1670\u20131680","journal-title":"Nat Protoc"},{"key":"563_CR30","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109982","volume":"37","author":"M Kinisu","year":"2021","unstructured":"Kinisu M, Choi YJ, Cattoglio C, Liu K, Roux de Bezieux H, Valbuena R, Pum N, Dudoit S, Huang H, Xuan Z et al (2021) Klf5 establishes bi-potential cell fate by dual regulation of ICM and TE specification genes. Cell Rep 37:109982","journal-title":"Cell Rep"},{"key":"563_CR31","volume":"384","author":"JA Klomp","year":"2024","unstructured":"Klomp JA, Klomp JE, Stalnecker CA, Bryant KL, Edwards AC, Drizyte-Miller K, Hibshman PS, Diehl JN, Lee YS, Morales AJ et al (2024) Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers. Science 384:eadk0775","journal-title":"Science"},{"key":"563_CR32","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ccr.2014.05.019","volume":"26","author":"HJ Lee","year":"2014","unstructured":"Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ, Settleman J (2014) Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer cell 26:207\u2013221","journal-title":"Cancer cell"},{"key":"563_CR33","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ccr.2011.03.009","volume":"19","author":"M Lesina","year":"2011","unstructured":"Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Kloppel G, Yoshimura A, Reindl W, Sipos B, Akira S et al (2011) Stat3\/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19:456\u2013469","journal-title":"Cancer Cell"},{"key":"563_CR34","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.immuni.2018.06.006","volume":"49","author":"J Li","year":"2018","unstructured":"Li J, Byrne KT, Yan F, Yamazoe T, Chen Z, Baslan T, Richman LP, Lin JH, Sun YH, Rech AJ et al (2018) Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy. Immunity 49:178\u2013193.e177","journal-title":"Immunity"},{"key":"563_CR35","volume":"120","author":"J Li","year":"2023","unstructured":"Li J, D\u2019Amico S, Kirillov V, Petrenko O, Reich NC (2023) Oncogenic dependency plays a dominant role in the immune response to cancer. Proc Natl Acad Sci USA 120:e2308635120","journal-title":"Proc Natl Acad Sci USA"},{"key":"563_CR36","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ccr.2005.10.014","volume":"8","author":"KH Lim","year":"2005","unstructured":"Lim KH, Counter CM (2005) Reduction in the requirement of oncogenic Ras signaling to activation of PI3K\/AKT pathway during tumor maintenance. Cancer Cell 8:381\u2013392","journal-title":"Cancer Cell"},{"key":"563_CR37","volume":"26","author":"K Liu","year":"2020","unstructured":"Liu K, Luo J, Shao C, Ren Z, Sun S, Zhu Y, Zhou H, Jiang Z, Li X, Gu W et al (2020) Synaptotagmin 12 (SYT12) gene expression promotes cell proliferation and progression of lung adenocarcinoma and involves the phosphoinositide 3-kinase (PI3K)\/AKT\/mammalian target of rapamycin (mTOR) pathway. Med Sci Monit 26:e920351","journal-title":"Med Sci Monit"},{"key":"563_CR38","doi-asserted-by":"crossref","unstructured":"Liu Y, Han J, Hsu WH, LaBella KA, Deng P, Shang X, Tallon de Lara P, Cai L, Jiang S, DePinho RA (2024) Combined KRAS inhibition and immune therapy generates durable complete responses in an autochthonous PDAC model. Cancer Discov 15:162\u2013178","DOI":"10.1158\/2159-8290.CD-24-0489"},{"key":"563_CR39","doi-asserted-by":"crossref","DOI":"10.1126\/science.adf1329","volume":"384","author":"D Mathew","year":"2024","unstructured":"Mathew D, Marmarelis ME, Foley C, Bauml JM, Ye D, Ghinnagow R, Ngiow SF, Klapholz M, Jun S, Zhang Z et al (2024) Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science 384:eadf1329","journal-title":"Science"},{"key":"563_CR40","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019102161","volume":"38","author":"M Milan","year":"2019","unstructured":"Milan M, Balestrieri C, Alfarano G, Polletti S, Prosperini E, Spaggiari P, Zerbi A, Diaferia GR, Natoli G (2019) FOXA2 controls the cis-regulatory networks of pancreatic cancer cells in a differentiation grade-specific manner. EMBO J 38:e102161","journal-title":"EMBO J"},{"key":"563_CR41","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/1878-0261.13751","volume":"19","author":"S Miyazaki","year":"2025","unstructured":"Miyazaki S, Kitazawa M, Nakamura S, Koyama M, Yamamoto Y, Hondo N, Kataoka M, Tanaka H, Takeoka M, Komatsu D et al (2025) Targeting KRAS-mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2. Mol Oncol 19:377\u2013390","journal-title":"Mol Oncol"},{"key":"563_CR42","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung AH et al (2015) Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet 47:1168\u20131178","journal-title":"Nat Genet"},{"key":"563_CR43","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1073\/pnas.1620861114","volume":"114","author":"H Mou","year":"2017","unstructured":"Mou H, Moore J, Malonia SK, Li Y, Ozata DM, Hough S, Song CQ, Smith JL, Fischer A, Weng Z et al (2017) Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis. Proc Natl Acad Sci USA 114:3648\u20133653","journal-title":"Proc Natl Acad Sci USA"},{"key":"563_CR44","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-00942-5","volume":"8","author":"MD Muzumdar","year":"2017","unstructured":"Muzumdar MD, Chen PY, Dorans KJ, Chung KM, Bhutkar A, Hong E, Noll EM, Sprick MR, Trumpp A, Jacks T (2017) Survival of pancreatic cancer cells lacking KRAS function. Nat Commun 8:1090","journal-title":"Nat Commun"},{"key":"563_CR45","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semcancer.2019.08.007","volume":"67","author":"D Novak","year":"2020","unstructured":"Novak D, Huser L, Elton JJ, Umansky V, Altevogt P, Utikal J (2020) SOX2 in development and cancer biology. Semin Cancer Biol 67:74\u201382","journal-title":"Semin Cancer Biol"},{"key":"563_CR46","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41422-019-0195-y","volume":"29","author":"J Peng","year":"2019","unstructured":"Peng J, Sun BF, Chen CY, Zhou JY, Chen YS, Chen H, Liu L, Huang D, Jiang J, Cui GS et al (2019) Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Cell Res 29:725\u2013738","journal-title":"Cell Res"},{"key":"563_CR47","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","volume":"185","author":"RL Philips","year":"2022","unstructured":"Philips RL, Wang Y, Cheon H, Kanno Y, Gadina M, Sartorelli V, Horvath CM, Darnell JE Jr, Stark GR, O\u2019Shea JJ (2022) The JAK-STAT pathway at 30: much learned, much more to do. Cell 185:3857\u20133876","journal-title":"Cell"},{"key":"563_CR48","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","volume":"19","author":"SR Punekar","year":"2022","unstructured":"Punekar SR, Velcheti V, Neel BG, Wong KK (2022) The current state of the art and future trends in RAS-targeted cancer therapies. Nat Rev Clin Oncol 19:637\u2013655","journal-title":"Nat Rev Clin Oncol"},{"key":"563_CR49","volume":"7","author":"J Reddy","year":"2021","unstructured":"Reddy J, Fonseca MAS, Corona RI, Nameki R, Segato Dezem F, Klein IA, Chang H, Chaves-Moreira D, Afeyan LK, Malta TM et al (2021) Predicting master transcription factors from pan-cancer expression data. Sci Adv 7:eabf6123","journal-title":"Sci Adv"},{"key":"563_CR50","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.cell.2017.07.007","volume":"170","author":"JS Roe","year":"2017","unstructured":"Roe JS, Hwang CI, Somerville TDD, Milazzo JP, Lee EJ, Da Silva B, Maiorino L, Tiriac H, Young CM, Miyabayashi K et al (2017) Enhancer reprogramming promotes pancreatic cancer metastasis. Cell 170:875\u2013888.e820","journal-title":"Cell"},{"key":"563_CR51","doi-asserted-by":"crossref","first-page":"e164413","DOI":"10.1172\/JCI164413","volume":"133","author":"M Salmon","year":"2023","unstructured":"Salmon M, Alvarez-Diaz R, Fustero-Torre C, Brehey O, Lechuga CG, Sanclemente M, Fernandez-Garcia F, Lopez-Garcia A, Martin-Guijarro MC, Rodriguez-Perales S et al (2023) Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas. J Clin Invest 133:e164413","journal-title":"J Clin Invest"},{"key":"563_CR52","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana NE, Shalem O, Zhang F (2014) Improved vectors and genome-wide libraries for CRISPR screening. Nat methods 11:783\u2013784","journal-title":"Nat methods"},{"key":"563_CR53","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01922-8","volume":"23","author":"G Seaton","year":"2024","unstructured":"Seaton G, Smith H, Brancale A, Westwell AD, Clarkson R (2024) Multifaceted roles for BCL3 in cancer: a proto-oncogene comes of age. Mol Cancer 23:7","journal-title":"Mol Cancer"},{"key":"563_CR54","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1172\/JCI59643","volume":"122","author":"A Sica","year":"2012","unstructured":"Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122:787\u2013795","journal-title":"J Clin Invest"},{"key":"563_CR55","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccr.2009.03.022","volume":"15","author":"A Singh","year":"2009","unstructured":"Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, Settleman J (2009) A gene expression signature associated with \u201cK-Ras addiction\u201d reveals regulators of EMT and tumor cell survival. Cancer cell 15:489\u2013500","journal-title":"Cancer cell"},{"key":"563_CR56","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.4161\/cc.8.17.9336","volume":"8","author":"A Singh","year":"2009","unstructured":"Singh A, Settleman J (2009) Oncogenic K-ras \u201caddiction\u201d and synthetic lethality. Cell Cycle 8:2676\u20132677","journal-title":"Cell Cycle"},{"key":"563_CR57","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-09-2979","volume":"70","author":"Y Song","year":"2010","unstructured":"Song Y, Washington MK, Crawford HC (2010) Loss of FOXA1\/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res 70:2115\u20132125","journal-title":"Cancer Res"},{"key":"563_CR58","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663\u2013676","journal-title":"Cell"},{"key":"563_CR59","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.pan.2016.02.004","volume":"16","author":"C Verbeke","year":"2016","unstructured":"Verbeke C (2016) Morphological heterogeneity in ductal adenocarcinoma of the pancreas\u2014does it matter?. Pancreatology 16:295\u2013301","journal-title":"Pancreatology"},{"key":"563_CR60","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3390\/cancers16071387","volume":"16","author":"W Wang","year":"2024","unstructured":"Wang W, Lopez McDonald MC, Hariprasad R, Hamilton T, Frank DA (2024) Oncogenic STAT transcription factors as targets for cancer therapy: innovative strategies and clinical translation. Cancers 16:1387","journal-title":"Cancers"},{"key":"563_CR61","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cell.2023.03.013","volume":"186","author":"CE Weeden","year":"2023","unstructured":"Weeden CE, Hill W, Lim EL, Gronroos E, Swanton C (2023) Impact of risk factors on early cancer evolution. Cell 186:1541\u20131563","journal-title":"Cell"},{"key":"563_CR62","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.celrep.2018.01.051","volume":"22","author":"TL Yuan","year":"2018","unstructured":"Yuan TL, Amzallag A, Bagni R, Yi M, Afghani S, Burgan W, Fer N, Strathern LA, Powell K, Smith B et al (2018) Differential effector engagement by oncogenic KRAS. Cell Rep 22:1889\u20131902","journal-title":"Cell Rep"},{"key":"563_CR63","volume":"384","author":"J Zak","year":"2024","unstructured":"Zak J, Pratumchai I, Marro BS, Marquardt KL, Zavareh RB, Lairson LL, Oldstone MBA, Varner JA, Hegerova L, Cao Q et al (2024) JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science 384:eade8520","journal-title":"Science"}],"container-title":["EMBO Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44319-025-00563-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44319-025-00563-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44319-025-00563-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T09:29:21Z","timestamp":1786958961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44319-025-00563-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":62,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,10,23]]}},"alternative-id":["563"],"URL":"https:\/\/doi.org\/10.1038\/s44319-025-00563-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.02.21.639533","asserted-by":"object"}]},"ISSN":["1469-221X","1469-3178"],"issn-type":[{"value":"1469-221X","type":"print"},{"value":"1469-3178","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}],"article-number":"4"}}